Abstract
Tardive dyskinesia (TD) is a long-term adverse effect of antipsychotic drugs that are dopamine D2 receptor blockers.1 Serotonin receptor antagonism has been proposed as a common mechanism contributing to the low extrapyramidal effects profile of atypical antipsychotic drugs.2 We examined the association of three polymorphisms in the 5-HT2A receptor gene (HTR2A) with TD susceptibility—T102C3 and his452tyr4 in the coding region and A-1438G5 in the promoter—in matched schizophrenia patients with (n = 59, SCZ-TD-Y) and without TD (n = 62, SCZ-TD-N) and normal control subjects (n = 96). The T102C and the A-1438G polymorphisms are in complete linkage disequilibrium but not his452tyr. There was a significant excess of 102C and −1438G alleles (62.7%) in the SCZ-TD-Y patients compared to SCZ-TD-N patients (41.1%) and controls (45.9%; χ2 = 12.8, df = 2, P = 0.002; SCZ-TD-Y vs SCZ-TD-N, χ2 = 11.4, df = 1, P = 0.0008, OR 2.41, 95% CI 1.43–3.99) and of 102CC and −1438GG genotypes (SCZ-TD-Y 42.4%, SCZ-TD-N, 16.1%, controls 20.8%, χ2 = 13.3, df = 4, P = 0.01). The 102CC and the −1438GG genotypes were associated with significantly higher AIMS trunk dyskinesia scores (F = 3.9; df = 2, 116; P = 0.02) and more incapacitation (F = 5.0; df = 2, 115; P = 0.006). The his452tyr polymorphism showed no association with TD. These findings suggest that the 5-HT2A receptor gene is significantly associated with susceptibility to TD in patients with chronic schizophrenia. Previously reported association of the T102C and A-1438G polymorphisms with schizophrenia6 may reflect association of a sub-group of patients with a susceptibility to abnormal involuntary movements related to antipsychotic drug exposure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kane JM, Smith JM . Tardive dyskinesia: prevalence and risk factors, 1959 to 1979 Arch Gen Psychiatry 1982 37: 473–481
Meltzer HY . The role of serotonin in antipsychotic drug action Neuropsychopharmacology 1999 21 Suppl 2: 106–115
Waren JT, Peacock ML, Rodriguez LC, Fink JK . An Mspl polymorphism in the human serotonin receptor gene: detection by DGGE and RFLP analysis Hum Mol Genet 1993 2: 338
Ozaki N, Rosenthal NE, Pesonen U . Two naturally occurring amino acid substitutions of the 5-HT2A receptor: similar prevalence in patients with seasonal affective disorder and controls Biol Psychiatry 1996 40: 1267–1272
Collier DA, Arranz MJ, Li T, Mupita D, Brown N, Treasure J . Association between 5-HT2A gene promoter polymorphism and anorexia nervosa Lancet 1997 350: 412
Williams J, McGuffin P, Nothen M, Owen MJ . Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia [letter] Lancet 1997 349: 1221
Belmaker RH, Bannet J, Brecher-Fried E . The effect of haloperidol feeding on dopamine receptor number in ten mouse strains Clin Genet 1981 19: 353–356
Rosengarten H, Schweitzter JW, Friedhoff AJ . Possible genetic factors underlying the pathophysiology of tardive dyskinesia Pharm Biochem Behav 1994 3: 633–667
Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K . Tardive dyskinesia and ethnicity: review of the literature Ann Clin Psychiatry 1997 9: 53–59
Weinhold P, Wegner JT, Kane JM . Familial occurrence of tardive dyskinesia J Clin Psychiatry 42: 165–166
Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagacev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor gene and tardive dyskinesia in chronic schizophrenia Mol Psychiatry 1999 4: 247–253
Steen VM, Llie R, McEwan T, McCreadie RG . Dopamine D3 receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients Mol Psychiatry 1997 2: 139–145
Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia Neuropsychopharmacology 1999 21: 17–27
Lovlie R, Daly AK, Blennerhassett R, Ferrier N, Steen VM . Homozygosity for Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients Int J Neuropsychopharmacol 2000 3: 61–66
Casey DE . Effects of clozapine therapy in schizophrenic individuals at risk for tardive dyskinesia J Clin Psychiatry 1998 59 Suppl 3: 31–37
Tamminga CA, Thaker GK, Moran M, Kakigi T, Gao XM . Clozapine in tardive dyskinesia: observations from human and animal model studies J Clin Psychiatry 1994 55 Suppl B: 102–106
Glazer WM . Expected incidence of tardive dyskinesia associated with atypical antipsychotics J Clin Psychiatry 2000 61: 21–26
Marazziti D, Rossi A, Palego L . [3H]ketanserin binding in human brain postmortem Neurochem Res 1997 22: 753–757
Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG . The role of 5-HT2A receptors in antipsychotic activity Life Sci 1995 56: 2209–2222
Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T . Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain J Neural Transm 2000 107: 295–302
Rubovits R, Klawans HL Jr . Implications of amphetamine induced stereotyped behavior as a model for tardive dyskinesia Arch Gen Psychiatry 1972 27: 502–507
Rosengarten H, Schweitzer JW, Friedhoff AJ . The effect of novel antipsychotics in rat oral dyskinesia Prog Neuropsychopharmacol Biol Psychiatry 1999 23: 1389–1404
Barwick VS, Jones DH, Richter JT, Hicks PB, Young KA . Subthalamic nucleus microinjections of 5-HT2 receptor antagonists suppress stereotypy in rats Neuroreport 2000 11: 267–270
Kostrzewa RM, Reader TA, Descarries L . Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain J Neurochem 1998 70: 889–898
Hsieh CL, Bowcock AM, Farrer LA, Hebert JM, Huang KM, Cavalli-Sforza LL et al. The serotonin receptor subtype 2 locus HTR2 is on chromosome 13 near genes for estherase D and retinoblastoma and on mouse chromosome 14 Somat Cell Genet 1990 16: 567–574
Erdmann J, Shimron-Abarbanell D, Rietschel M . Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: identification of two naturally occurring receptor variants and association analysis in schizophrenia Hum Genet 1996 97: 614–619
Ohara K, Ino A, Ishigaki T, Tani K, Tsukamoto T, Nakamura Y . Analysis of the 5′-flanking promoter region of the 5-HT2A receptor gene in schizophrenia Neuropsychopharmacology 1997 17: 274–278
Spurlock G, Heils A, Holmans P, Williams J, D'Souza UM, Cardno A et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter Mol Psychiatry 1998 3: 42–49
Tay AH, Lim LC, Lee WL, Wong KE, Wong LY, Tsoi WF . Association between allele 1 of T102C polymorphism, 5-hydroxytryptamine 2a receptor gene and schizophrenia in Chinese males in Singapore Hum Hered 1997 47: 298–300
Hawi Z, Myakishev MV, Straub RE . No association or linkage between the 5-HT2a/T102C polymorphism and schizophrenia in Irish families Am J Med Genet 1997 74: 370–373
Kouzmenko AP, Scaffidi A, Pereira AM, Hayes WL, Copolov DL, Dean B . No correlation between A(-1438)G polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia Hum Hered 1999 49: 103–105
Ohara K, Nagai M, Tani K, Tsukamoto T . Schizophrenia and the serotonin-2A receptor promoter polymorphism Psychiatry Res 1999 85: 221–224
Shinkai T, Ohmori O, Kojima H, Terao T, Suzuki T, Abe K . Negative association between T102C polymorphism of the 5-HT2a receptor gene and schizophrenia in Japan Hum Hered 1998 48: 212–215
Arranz MJ, Munro J, Sham P . Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response Schizophr Res 1998 32: 93–99
Masellis M, Basile V, Meltzer HY . Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients Neuropsychopharmacology 1998 19: 123–132
Malhotra AK, Goldman D, Ozaki N, Breier A, Buchanan R, Pickar D . Lack of association between polymorphisms in the 5-HT2A receptor gene and the antipsychotic response to clozapine Am J Psychiatry 1996 153: 1092–1094
Turecki G, Briere R, Dewar K . Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide Am J Psychiatry 1999 156: 1456–1458
Nacmias B, Ricca V, Tedde A, Mezzani B, Rotella CM, Sorbi S . 5-HT2A receptor gene polymorphism in anorexia nervosa and bulimia nervosa Neurosci Lett 1999 277: 134–136
Muscettola G, Giuseppe B, Pampallona S, Casiello M, Bolini P . Extrapyramidal syndromes in neuroleptic-treated patients: prevalence risk factors and association with tardive dyskinesia J Clin Psychopharmacol 1999 19: 203–208
Paulsen JS, Caligiuri MP, Palmer B, McAdams LA, Jeste DV . Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study Psychopharmacology (Berl) 1996 123: 307–314
Gureje O . Topographic subtypes of TD in schizophrenic patients aged less than 60 years: relationship to demographic clinical treatment and neuropsychological variables J Neurol Neurosurg Psychiatry 1988 51: 1525–1530
Glazer WM, Morgenstern H, Niedzweicki D, Hughes J . Heterogeneity of tardive dyskinesia. A multivariate analysis Br J Psychiatry 1988 152: 253–259
Schooler NR, Kane JM . Research diagnoses for tardive dyskinesia Arch Gen Psychiatry 1982 39: 486–487
Guy W . ECDEU Assessment Manual for Psychopharmacology, revised edition Department of Health, Education and Welfare, Washington DC 1976
Kay SR, Opler LA . Positive and Negative Syndrome Scale (PANSS) Rating Manual Social and Behavioral Sciences Documents San Rafael, CA 1987
Simpson GM, Angus JWS . A rating scale for extrapyramidal side effects Acta Psychiatr Scand 1970 212: (Suppl) 11–19
Acknowledgements
This work was supported in part by grants from the Yisumi Fund of Hadassit Research and Development Corporation and the National Institute for Psychobiology in Israel (to RS) and the India–Israel Human Genome Collaboration (to BL). The Biological Psychiatry Laboratory, Hadassah–Hebrew University Medical Center (http://www.hadassah.org.il/departments/biopsyc/), is supported by the Harry Stern Family Foundation.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Segman, R., Heresco-Levy, U., Finkel, B. et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6, 225–229 (2001). https://doi.org/10.1038/sj.mp.4000842
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.mp.4000842
Keywords
This article is cited by
-
Prognostication of Functional Outcomes of Schizophrenia Using a Multigene Panel
Neuroscience and Behavioral Physiology (2022)
-
The genetics of drug-related movement disorders, an umbrella review of meta-analyses
Molecular Psychiatry (2020)
-
Genetics of psychotropic medication induced side effects in two independent samples of bipolar patients
Journal of Neural Transmission (2015)
-
Do Tardive Dyskinesia and l-Dopa Induced Dyskinesia Share Common Genetic Risk Factors? An Exploratory Study
Journal of Molecular Neuroscience (2013)
-
Support for association of HSPG2 with tardive dyskinesia in Caucasian populations
The Pharmacogenomics Journal (2012)